NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Cybin's U.S. Listing Transfer to Nasdaq and Ticker Change to HELP
TL;DR
Cybin's move to Nasdaq with the 'HELP' ticker could enhance investor visibility and attract growth capital for its mental health treatments.
Cybin will transfer from NYSE American to Nasdaq on January 5, 2026, changing its ticker to 'HELP' while maintaining its Cboe Canada listing.
This strategic move supports Cybin's mission to develop innovative mental health treatments, potentially improving care for millions suffering from depression and anxiety.
Cybin's new 'HELP' ticker symbol on Nasdaq cleverly aligns with its mission to revolutionize mental healthcare through novel psychedelic-based therapies.
Found this article helpful?
Share it with your network and spread the knowledge!
Cybin Inc. announced plans to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market and change its ticker symbol from 'CYBN' to 'HELP'.
Cybin's common shares will cease trading on NYSE American at market close on January 4, 2026, and begin trading on Nasdaq at market open on January 5, 2026, with the new 'HELP' ticker symbol.
Cybin will remain listed on Cboe Canada and will also trade under the 'HELP' ticker symbol on that exchange beginning January 5, 2026.
While the content doesn't explicitly state the reasons, the announcement positions Cybin as a company committed to revolutionizing mental healthcare, and the 'HELP' ticker symbol aligns with its mission to address unmet mental health needs.
Cybin is a clinical-stage pharmaceutical company (described as a late-stage breakthrough neuropsychiatry company) developing next-generation mental health treatments, with operations in Canada, the United States, the United Kingdom, and Ireland.
Cybin is developing CYB003 (a deuterated psilocin analog) in Phase 3 studies for major depressive disorder and CYB004 (a deuterated N, N-dimethyltryptamine molecule) in a Phase 2 study for generalized anxiety disorder, plus a research pipeline of 5-HT-receptor focused compounds.
You can view the full press release at https://ibn.fm/pcrpA and find the latest news and updates relating to CYBN in the company's newsroom at https://ibn.fm/CYBN.
Cybin's CYB003 program has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, which indicates the FDA recognizes its potential to address unmet medical needs and may expedite its development and review.
Curated from InvestorBrandNetwork (IBN)
